CN113768587A - 一种治疗难治性癌痛的椎管内镇痛导管置入*** - Google Patents
一种治疗难治性癌痛的椎管内镇痛导管置入*** Download PDFInfo
- Publication number
- CN113768587A CN113768587A CN202110845666.7A CN202110845666A CN113768587A CN 113768587 A CN113768587 A CN 113768587A CN 202110845666 A CN202110845666 A CN 202110845666A CN 113768587 A CN113768587 A CN 113768587A
- Authority
- CN
- China
- Prior art keywords
- tube
- needle
- sheath
- vascular sheath
- analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 29
- 230000036407 pain Effects 0.000 title claims abstract description 27
- 238000002513 implantation Methods 0.000 title claims abstract description 16
- 206010070308 Refractory cancer Diseases 0.000 title claims abstract description 11
- 208000016691 refractory malignant neoplasm Diseases 0.000 title claims abstract description 11
- 230000036592 analgesia Effects 0.000 title abstract description 10
- 230000002792 vascular Effects 0.000 claims abstract description 49
- 230000000202 analgesic effect Effects 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims abstract description 9
- 239000000741 silica gel Substances 0.000 claims abstract description 9
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 9
- 230000000916 dilatatory effect Effects 0.000 claims abstract 2
- 238000003780 insertion Methods 0.000 claims description 11
- 230000037431 insertion Effects 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 7
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 206010033675 panniculitis Diseases 0.000 claims description 6
- -1 polyethylene Polymers 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000000249 desinfective effect Effects 0.000 claims description 3
- 238000002594 fluoroscopy Methods 0.000 claims description 3
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 claims description 3
- 229960004359 iodixanol Drugs 0.000 claims description 3
- 239000007769 metal material Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 210000000115 thoracic cavity Anatomy 0.000 claims description 3
- 210000003815 abdominal wall Anatomy 0.000 claims description 2
- 230000005641 tunneling Effects 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 abstract description 18
- 201000011510 cancer Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 230000007774 longterm Effects 0.000 abstract description 6
- 229940035676 analgesics Drugs 0.000 abstract description 4
- 239000000730 antalgic agent Substances 0.000 abstract description 4
- 206010067484 Adverse reaction Diseases 0.000 abstract description 3
- 230000006838 adverse reaction Effects 0.000 abstract description 3
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 238000013461 design Methods 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 20
- 206010058019 Cancer Pain Diseases 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 229960005181 morphine Drugs 0.000 description 10
- 238000001802 infusion Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 description 3
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 3
- 208000004404 Intractable Pain Diseases 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 229960003150 bupivacaine Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 229960003617 oxycodone hydrochloride Drugs 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 239000007939 sustained release tablet Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000002330 subarachnoid space Anatomy 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010071368 Psychological trauma Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000773 effect on pain Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 238000009102 step therapy Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3401—Puncturing needles for the peridural or subarachnoid space or the plexus, e.g. for anaesthesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M19/00—Local anaesthesia; Hypothermia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/06—Body-piercing guide needles or the like
- A61M25/0662—Guide tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/06—Body-piercing guide needles or the like
- A61M25/0662—Guide tubes
- A61M2025/0681—Systems with catheter and outer tubing, e.g. sheath, sleeve or guide tube
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Anesthesiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
本发明属于医疗技术领域,具体涉及一种治疗难治性癌痛的椎管内镇痛导管置入***。所述的置入***包括外部套有套管的穿刺针;能内置在所述套管的导丝;能内置所述导丝的血管鞘;能内置在所述血管鞘内部,并内置所述导丝的扩张管;能内置在所述血管鞘中的PICC管;本发明采用高级医用硅胶,生物相容性极佳,适于中长期留置,采用三向瓣膜设计,防止脑脊液返流,降低堵管率,极大地减轻了患者的经济负担,本发明所述的鞘内镇痛镇痛效果确切、起效快、副作用小,镇痛药物用量仅为口服剂量的1/300。该方法操作便捷,疗效确切,不良反应小,极大地减轻了患者的经济负担,适合应用于晚期癌痛患者。
Description
技术领域
本发明属于医疗技术领域,具体涉及一种治疗难治性癌痛的椎管内镇痛导管置入***。
背景技术
疼痛是一种与实际或潜在组织损伤相关的感觉、情绪、认知和社会成分的痛苦体验。癌症是威胁人类生存的首要疾病之一,癌症疼痛(以下简称“癌痛”)是最常见的癌症相关症状之一。癌性疼痛为肿瘤本身或其相关性疾病所致的疼痛,包括癌症相关疼痛、癌症治疗相关性疼痛,以及其他原因引起的疼痛。据统计,约25%初诊癌症病人、55%正在接受治疗的癌症病人及66%晚期癌症病人均有癌痛症状。癌痛不仅影响患者的生活质量,而且持续剧烈的顽固性疼痛往往会对患者及其家庭造成严重的心理创伤,同时长期的疼痛刺激可引起中枢神经***的病理性重构,导致疼痛疾病的进展和愈加难以控制。药物治疗是癌痛患者最基本的治疗方法,多数癌痛患者按照三阶梯治疗原则治疗后得到明显的控制,但仍有10%~30%的癌痛采用药物治疗疼痛不能得到有效控制,或者因药物不良反应无法接受药物治疗。
鞘内镇痛是将镇痛药物注入蛛网膜下腔,经脑脊液循环直接作用于脊髓、脑产生镇痛作用,其优点是镇痛效果确切、起效快、副作用小。1979年Wang等首次采用***经蛛网膜下腔内注射治疗癌痛取得了满意的疗效。通过鞘内持续给药,能够实现长期镇痛的目的。
目前临床上常用的鞘内给药输注***分为全植入式和半植入式鞘内药物。全植入式***具有感染率低、患者舒适度高、管理便捷等优点,但其创伤较大,药物储存量小,价格较高,大多数患者无力承受其昂贵的费用。半植入式***创伤小,药物储存量大,费用较低,适合预计生存期较短的晚期癌痛患者。鞘内植入药物输注***近年来国内外在治疗晚期癌疼痛方面取得了良好的临床效果,对于药物及其他镇痛方法不能缓解的疼痛具有较理想的疗效。但其价格费用昂贵,患者难以承受。针对上述技术问题,本发明提供了一种治疗难治性癌痛的椎管内镇痛导管置入***,为癌痛患者带来福音。
发明内容
本发明提供了一种治疗难治性癌痛的椎管内镇痛导管置入***,所述的置入***包括外部套有套管的穿刺针,用于进行皮肤或血管穿刺;能内置在所述套管的导丝,用于引导其他进入的装置;能内置所述导丝的血管鞘;能内置在所述血管鞘内,并内置所述导丝的扩张管,用于扩张通路,便于PICC管的***;能内置在所述血管鞘中的PICC管,留置在血管或椎管中,用于采样或用药;所述的穿刺针包括固定连接的针座和针管,所述针座内空,与所述针管连通,所述的针管部分由金属材料制备而成,所述的针座部分由聚乙烯材料制备而成;所述的套管由聚乙烯材料制备而成,套管的内径大于针管的外径,所述的套管嵌套在穿刺针的针管上,裸露穿刺针的针头,尾部与针座可拆卸的连接;所述的导丝头部弯曲,长度为10-50cm,储存于储存管中;所述血管鞘包括鞘座,所述鞘座的尾端连接有连接管,所述鞘座的头端固定连接有鞘管,所述连接管与所述鞘管、鞘座连通;所述扩张管包括扩张管座和扩张管体,扩张管座与扩张管体固定连接,所述扩张管体的外径小于血管鞘鞘管的内径,长度比血管鞘鞘管长5-10mm;所述的PICC管由硅胶制备而成,外径小于血管鞘鞘管的内径,所述的硅胶为高级医用硅胶,生物相容性极佳,适于中长期留置。
优选的,所述的导丝为医用导丝。
优选的,所述的置入***还包括隧道穿刺针、连接件以及固定装置;所述的固定装置为STATLOCK固定装置,所述的隧道穿刺针为医用穿刺针,所述的连接件为医用连接件,均为常规医疗器械。利用上述装置建立皮下隧道,将所述的PICC管沿着皮下组织向左后背部外侧刺入至侧腹部,以减少感染。
优选的,所述的导丝长度为20-30cm。
优选的,所述的导丝长度为25cm。
优选的,所述的PICC管为三向瓣膜PICC管,可以防止脑脊液返流,降低堵管率。
本发明的有益效果是:
①本发明采用三向瓣膜PICC管进行鞘内置管外接电子PCA泵的方法,采用高级医用硅胶,生物相容性极佳,适于中长期留置,采用三向瓣膜设计,防止脑脊液返流,降低堵管率,患者带管回家更方便,所述的PICC管腔内径0.033,重力流速为540ml/hr,维护方便,完全符合鞘内给药的要求。
②该方法操作便捷,疗效确切,不良反应小,费用仅为进口全植入式药物灌注***的1/1000,为输液港式半植入输注***的1/5,极大地减轻了患者的经济负担,适合应用于晚期癌痛患者。
③本发明所述的鞘内镇痛是将镇痛药物注入蛛网膜下腔,经脑脊液循环直接作用于脊髓、脑产生镇痛作用,其优点是镇痛效果确切、起效快、副作用小,镇痛药物用量仅为口服剂量的1/300。
④该方法操作便捷,疗效确切,不良反应小,费用仅为进口全植入式药物灌注***的1/1000,为输液港式半植入输注***的1/5,极大地减轻了患者的经济负担,适合应用于晚期癌痛患者。
附图说明
图1外部套有套管2的穿刺针1的示意图
图2导丝3的示意图
图3扩张管4的示意图
图4血管鞘5的示意图
图5PICC管6的示意图
图6隧道穿刺针7的示意图
图7连接件8的示意图
具体实施方式
实施例一、一种治疗难治性癌痛的椎管内镇痛导管置入***
本发明提供了一种治疗难治性癌痛的椎管内镇痛导管置入***,所述的置入***包括外部套有套管2的穿刺针1,用于进行皮肤或血管穿刺;能内置在所述套管的导丝3,用于引导其他进入的装置;能内置所述导丝3的血管鞘5;能内置在所述血管鞘5内,并内置所述导丝3的扩张管4,用于扩张通路,便于PICC管6的***;能内置在所述血管鞘中5的PICC管6,留置在血管或椎管中,用于采样或用药;所述的穿刺针1包括固定连接的针座和针管,所述针座内空,与所述针管连通,所述的针管部分由金属材料制备而成,所述的针座部分由聚乙烯材料制备而成;所述的套管2由聚乙烯材料制备而成,套管的内径大于针管的外径,所述的套管嵌套在穿刺针的针管上,裸露穿刺针的针头,尾部与针座可拆卸的连接;所述的导丝3头部弯曲,长度为10-50cm,储存于储存管中;所述血管鞘5包括鞘座,所述鞘座的尾端连接有连接管,所述鞘座的头端固定连接有鞘管,所述连接管与所述鞘管、鞘座连通;所述扩张管4包括扩张管座和扩张管体,扩张管座与扩张管体固定连接,所述扩张管体的外径小于血管鞘鞘管的内径,长度比血管鞘鞘管长5-10mm;所述的PICC管6由硅胶制备而成,外径小于血管鞘鞘管的内径,所述的硅胶为高级医用硅胶,生物相容性极佳,适于中长期留置。所述的导丝3为医用导丝。所述的置入***还包括隧道穿刺针7、连接件8以及固定装置;所述的固定装置为STATLOCK固定装置,所述的隧道穿刺针为医用穿刺针,所述的连接件为医用连接件,均为常规医疗器械。利用上述装置建立皮下隧道,将所述的PICC管6沿着皮下组织向左后背部外侧刺入至侧腹部,以减少感染。所述的导丝3长度为25cm。所述的PICC管6为三向瓣膜PICC管,可以防止脑脊液返流,降低堵管率。
实施例二、一种治疗难治性癌痛的椎管内镇痛导管置入***的使用方法
(1)选择穿刺点,常规消毒铺巾,穿刺点做局部浸润麻醉;
(2)用尖刀片切开切口3mm,钝性分离皮下组织,在C臂透视引导下将所述外部套有套管2的穿刺针1成功穿刺至蛛网膜下腔,拔出穿刺针1后见脑脊液回流通畅;
(3)经套管2置入导丝3,退出套管2,经导丝3置入所述血管鞘5和扩张管4,退出导丝3和扩张管4,经血管鞘5注入碘克沙醇1ml证实血管鞘5头端位于蛛网膜下腔内;
(4)遂经血管鞘5尾端置入PICC管6,头端置于胸11椎体水平,保留PICC管6,退出血管鞘5;
(5)用0.5%利多卡因沿穿刺点向左后背部行皮下浸润麻醉,用隧道穿刺针7经穿刺点切口内沿皮下组织向左后背部外侧刺入至侧腹部,穿出皮肤,建立皮下隧道,退出针芯,经穿刺针套管置入导丝3,退出隧道穿刺针7,沿导丝经外侧逆行置入血管鞘5至棘突间穿刺点切口处,退出导丝3及扩张管4,将PICC管6经血管鞘5引至侧腹壁外侧,保留PICC管6,退出血管鞘5,尾端连接连接件8,局部粘贴缝合,STATLOCK固定装置固定。
实施例三、一种治疗难治性癌痛的椎管内镇痛导管置入***的应用案例
发明人利用本发明所述的置入***为1例晚期癌痛患者持续泵入***,治疗效果良好,具体操作如下:
患者女性,57岁,主因“自诉下腹部、盆腔、腰骶部顽固性疼痛6月,加重2月,收住,1年前确诊为宫颈恶性肿瘤,在肿瘤内科给予全身化疗和放疗。自诉下腹部、盆腔、腰骶部顽固性疼痛,疼痛性质为持续胀痛,VAS评分8-10分,睡眠、饮食欠佳,影像学检查提示:宫颈占位合并多发骨转移。每日口服盐酸羟考酮缓释片320mg,镇痛效果不佳,服药后有轻度恶心,伴重度便秘。查体:患者精神憔悴,体质消瘦,小腹部可触及不规则肿块,移动性差,小腹部、腰骶部及髂部多处压痛明显,翻身及活动受限。
1.术前准备:术前常规检查肝肾功能、血常规、凝血无明显异常,腰椎MRI检查排除椎管内无占位。
2.材料:采用本发明所述的椎管内镇痛导管置入***
3.手术方式:患者术前禁食4小时,术中采用右侧卧位,监测血压、脉搏、呼吸、动态心电图及氧饱和度监测,建立静脉通道。选择L4-5棘突间隙为穿刺点,常规消毒铺巾,穿刺点用5%利多卡因做局部浸润麻醉,用尖刀片切开切口3mm,钝性分离皮下组织,在C臂透视引导下将所述外部套有套管2的穿刺针1成功穿刺至蛛网膜下腔,拔出穿刺针1后见脑脊液回流通畅,经套管2置入导丝3,退出套管2,经导丝3置入6F桡动脉血关鞘5和扩张管4,退出导丝3和扩张管4,经血管鞘5注入碘克沙醇1ml证实血管鞘5头端位于蛛网膜下腔内,遂经血管鞘5尾端置入PICC管6,头端置于胸11椎体水平,保留PICC管6,退出血管鞘5。
用0.5%利多卡因沿穿刺点向左后背部行皮下浸润麻醉,用18G15cm隧道穿刺针7经穿刺点切口内沿皮下组织向左后背部外侧刺入至侧腹部,穿出皮肤,建立皮下隧道,退出针芯,经隧道穿刺针套管置入导丝3,退出隧道穿刺针套管,沿导丝3经外侧逆行置入6F血管鞘5至棘突间穿刺点切口处,退出导丝3及扩张管4,将PICC管6经血管鞘引至侧腹壁外侧,保留PICC管6,退出血管鞘5,尾端局部粘贴缝合固定。随后进行药物滴定,因患者每日口服盐酸羟考酮缓释片320mg,换算为***量为640mg,以1/300作为鞘内背景输注量则鞘内***滴定量不超过2mg.先以0.5mg***+生理盐水共5ml蛛网膜下腔内注射,5分钟后患者诉疼痛可缓解50%,观察15分钟后患者无不适症状,随后在蛛网膜下腔内再次注射0.5mg***+生理盐水共5ml,观察5分钟后患者诉疼痛完全缓解,完成鞘内滴定。
4.药物配置:盐酸***注射液100mg+布比卡因75mg用0.9%氯化钠注射液稀释至250ml注入微量电子泵内(电子泵品牌),采用***起始剂量按照转换剂量(所用阿片类均转换为24h口服***量,其1/300作为鞘内背景量),,布比卡因起始剂量3~6mg,并设置单次冲击量为背景剂量的1/10,锁定时间30min。鞘内给药开始后停用所有阿片类镇痛药物,并且24小时根据患者疼痛缓解情况调整鞘内***和布比卡因剂量。鞘内给药后第一个24小时心电监护监测生命体征。
5.疗效:患者接受鞘内给药后疼痛明显缓解,VAS评分为2~3分,无呼吸抑制、头痛、未出现恶心呕吐,无尿潴留及皮肤瘙痒,无下肢感觉和运动障碍,出院后连续2月疼痛明显减轻,生活质量明显改善。
Claims (7)
1.一种治疗难治性癌痛的椎管内镇痛导管置入***,其特征在于,所述的置入***包括外部套有套管的穿刺针;
能内置在所述套管的导丝;
能内置所述导丝的血管鞘;
能内置在所述血管鞘内部,并内置所述导丝的扩张管;
能内置在所述血管鞘中的PICC管;
所述的穿刺针包括固定连接的针座和针管,所述针座内空,与所述针管连通,所述的针管部分由金属材料制备而成,所述的针座部分由聚乙烯材料制备而成;所述的套管由聚乙烯材料制备而成,套管的内径大于针管的外径,所述的套管嵌套在穿刺针的针管上,裸露穿刺针的针头,尾部与针座可拆卸的连接;所述的导丝头部弯曲,长度为10-50cm,储存于储存管中;所述血管鞘包括鞘座,所述鞘座的尾端连接有连接管,所述鞘座的头端固定连接有鞘管,所述连接管与所述鞘管、鞘座连通;所述扩张管包括扩张管座和扩张管体,扩张管座与扩张管体固定连接,所述扩张管体的外径小于血管鞘鞘管的内径,长度比血管鞘鞘管长5-10mm;所述的PICC管由硅胶制备而成,外径小于血管鞘鞘管的内径。
2.如权利要求1所述的椎管内镇痛导管置入***,其特征在于,所述的导丝为医用导丝。
3.如权利要求1所述的椎管内镇痛导管置入***,其特征在于,所述的置入***还包括隧道穿刺针、连接件以及固定装置;所述的固定装置为STATLOCK固定装置,所述的隧道穿刺针为医用穿刺针,所述的连接件为医用连接件。
4.如权利要求1所述的椎管内镇痛导管置入***,其特征在于,所述的导丝长度为20-30cm。
5.如权利要求1所述的椎管内镇痛导管置入***,其特征在于,所述的导丝长度为25cm。
6.如权利要求1所述的椎管内镇痛导管置入***,其特征在于,所述的PICC管为三向瓣膜PICC管。
7.如权利要求1所述的椎管内镇痛导管置入***的操作方法,其特征在于,所述的方法包括如下步骤:
(1)选择穿刺点,常规消毒铺巾,穿刺点做麻醉;
(2)用尖刀片切开切口,分离皮下组织,在C臂透视引导下将所述外部套有套管2的穿刺针1成功穿刺至蛛网膜下腔,拔出穿刺针1后见脑脊液回流通畅;
(3)经套管2置入导丝3,退出套管2,经导丝3置入所述血管鞘5和扩张管4,退出导丝3和扩张管4,经血管鞘5注入碘克沙醇1ml证实血管鞘5头端位于蛛网膜下腔内;
(4)遂经血管鞘5尾端置入PICC管6,头端置于胸11椎体水平,保留PICC管6,退出血管鞘5;
(5)用隧道穿刺针7建立皮下隧道,经穿刺针套管置入导丝3,退出隧道穿刺针7,沿导丝经外侧逆行置入血管鞘5至棘突间穿刺点切口处,退出导丝3及扩张管4,将PICC管6经血管鞘5引至侧腹壁外侧,保留PICC管6,退出血管鞘5,尾端连接连接件8,局部粘贴缝合,STATLOCK固定装置固定。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110845666.7A CN113768587A (zh) | 2021-07-26 | 2021-07-26 | 一种治疗难治性癌痛的椎管内镇痛导管置入*** |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110845666.7A CN113768587A (zh) | 2021-07-26 | 2021-07-26 | 一种治疗难治性癌痛的椎管内镇痛导管置入*** |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113768587A true CN113768587A (zh) | 2021-12-10 |
Family
ID=78836128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110845666.7A Pending CN113768587A (zh) | 2021-07-26 | 2021-07-26 | 一种治疗难治性癌痛的椎管内镇痛导管置入*** |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113768587A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040147877A1 (en) * | 2003-01-27 | 2004-07-29 | Heuser Richard R | Catheter introducer system |
CN103990219A (zh) * | 2013-02-17 | 2014-08-20 | 冯丹 | 一种适用于晚期癌痛患者的镇痛方法及设置 |
CN104174107A (zh) * | 2013-05-21 | 2014-12-03 | 北京迪玛克医药科技有限公司 | 一种新型血管鞘 |
CN106215276A (zh) * | 2016-08-31 | 2016-12-14 | 北京兆仕医疗器械有限责任公司 | 一种蛛网膜下腔硬膜外椎管给药装置 |
CN108126267A (zh) * | 2018-02-10 | 2018-06-08 | 威海吉威重症医疗制品有限公司 | 一种picc导管 |
CN108578878A (zh) * | 2018-05-07 | 2018-09-28 | 北京迈迪顶峰医疗科技有限公司 | 血管鞘组及利用其微创建立血管介入通路的方法 |
CN110353778A (zh) * | 2019-07-30 | 2019-10-22 | 福建医科大学附属第一医院 | 一种用于腰椎穿刺蛛网膜下腔置管引导装置 |
CN111616779A (zh) * | 2020-06-08 | 2020-09-04 | 刘阳 | 一种双向导入血管穿刺装置 |
CN211434652U (zh) * | 2019-07-25 | 2020-09-08 | 汇康(昆山)医疗科技有限公司 | 一种鞘管管体带多孔结构的导管鞘 |
-
2021
- 2021-07-26 CN CN202110845666.7A patent/CN113768587A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040147877A1 (en) * | 2003-01-27 | 2004-07-29 | Heuser Richard R | Catheter introducer system |
CN103990219A (zh) * | 2013-02-17 | 2014-08-20 | 冯丹 | 一种适用于晚期癌痛患者的镇痛方法及设置 |
CN104174107A (zh) * | 2013-05-21 | 2014-12-03 | 北京迪玛克医药科技有限公司 | 一种新型血管鞘 |
CN106215276A (zh) * | 2016-08-31 | 2016-12-14 | 北京兆仕医疗器械有限责任公司 | 一种蛛网膜下腔硬膜外椎管给药装置 |
CN108126267A (zh) * | 2018-02-10 | 2018-06-08 | 威海吉威重症医疗制品有限公司 | 一种picc导管 |
CN108578878A (zh) * | 2018-05-07 | 2018-09-28 | 北京迈迪顶峰医疗科技有限公司 | 血管鞘组及利用其微创建立血管介入通路的方法 |
CN211434652U (zh) * | 2019-07-25 | 2020-09-08 | 汇康(昆山)医疗科技有限公司 | 一种鞘管管体带多孔结构的导管鞘 |
CN110353778A (zh) * | 2019-07-30 | 2019-10-22 | 福建医科大学附属第一医院 | 一种用于腰椎穿刺蛛网膜下腔置管引导装置 |
CN111616779A (zh) * | 2020-06-08 | 2020-09-04 | 刘阳 | 一种双向导入血管穿刺装置 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080058768A1 (en) | Central Nervous System Administration of Medications by Means of Pelvic Venous Catheterization and Reversal of Batson's Plexus | |
US20070213688A1 (en) | Infiltration cannula | |
Malhotra et al. | Intercostal blocks with local infiltration anesthesia for extracorporeal shock wave lithotripsy | |
Wills | Rapid onset of massive subdural anesthesia | |
Trivedi et al. | Interpleural block: a new technique for regional anaesthesia during percutaneous nephrostomy and nephrolithotomy | |
CN113768587A (zh) | 一种治疗难治性癌痛的椎管内镇痛导管置入*** | |
Knudsen et al. | Anesthesia and complications of extracorporeal shock wave lithotripsy of urinary calculi | |
RU2819991C1 (ru) | Способ проведения обезболивания при хроническом болевом синдроме у онкологических больных путем паравертебральной блокады под ультразвуковым контролем | |
CN214484586U (zh) | 一种无痛分娩用麻药施药装置 | |
CN217645597U (zh) | 一种用于腰大池的持续引流装置 | |
CN107174755B (zh) | 颅内放、化疗一体双腔子母囊 | |
CN200998472Y (zh) | 术后局部麻醉镇痛包 | |
RU2800569C1 (ru) | Способ лечения гнойных спондилодисцитов поясничного отдела позвоночника | |
RU2504369C1 (ru) | Способ пролонгированного обезболивания в раннем послеоперационном периоде у больных геморроем iii-iv стадии | |
SU1033141A1 (ru) | Способ лечени деструктивного панкреатита | |
Tay et al. | Timely detection of epidural catheter migration: diagnosis and management: a case report | |
CN202198976U (zh) | 一种多功能颅内肿瘤间质放化疗泵 | |
Lawson et al. | Pain management | |
KR20160144019A (ko) | 통증 조절용 카테터 장치 | |
RU2203654C1 (ru) | Способ обезболивания при родовспоможении | |
RU2185199C2 (ru) | Способ эпидуральной анестезии | |
Howle et al. | Non-neuraxial Options for Labour Analgesia | |
Tandon et al. | EPILEPSY, FUNCTIONAL, AND PAIN NEUROSURGERY | |
Zampella et al. | Percutaneous techniques for trigeminal neuralgia | |
RU2141787C1 (ru) | Способ регионарной гепатотропной терапии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211210 |
|
RJ01 | Rejection of invention patent application after publication |